Breathe Well Live Well
|
Asthma Capitals 2013: Virginia Takes the Top 'Honor'
Allergic Living Richmond, Virginia has been selected as 2013's most challenging place to live for people with asthma in the United States. In May, the Asthma and Allergy Foundation of America (AAFA) released its annual Asthma Capitals list – which ranks the 100 … Cleaning the right way to remove allergens |
View full post on asthma – Google News
 U.S. News & World Report |
Are You Allergic to the United States?
U.S. News & World Report That protection doesn't last forever, however: People who have been in the United States for at least a decade lose that protection and are more likely to develop asthma, hay fever and eczema, according to the study, published in the Journal of the … US-born kids have more allergies, asthma Being Born in the U.S. Increases Children's Risk of Allergic Diseases Kids born outside the US have lower allergy risk |
View full post on asthma – Google News
|
Allergy control helps prevent asthma, allergic conditions: Part 2 | Column
Bothell/Kenmore Reporter And nearly half of the people who have hay fever may eventually develop some form of asthma. A recent study shows that 75 percent of people with asthma aged 20 to 40, and 65 percent of those ages 55 and older, have at least one allergy. The results … |
View full post on asthma – Google News
 ABC Action News |
Asthma and Allergy Foundation: Most Allergic Cities in U.S.
ABC Action News The Asthma and Allergy Foundation has released its list of the "Most Allergic Cities in America." The rankings are based on pollen scores, over the counter and prescription allergy medications and the number of board certified allergists per patient … |
View full post on asthma – Google News
 KSEE |
Oral drops are good for treating symptoms of allergies, allergic asthma in …
News-Medical.net The report is believed to be the largest synopsis of its kind, reviewing previous research comparing various therapies designed to stop the wheezing, sneezing and runny nose that accompany allergic rhinoconjunctivitis and allergic asthma, researchers say. Analysis: Allergy drops a good alternative to shots |
View full post on asthma – Google News
|
Review article examines sublingual immunotherapy for treatment of allergic …
EurekAlert (press release) In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous studies to support the use of … |
View full post on asthma – Google News
|
Age not a major factor in asthma allergic sensitization rates
News-Medical.net "Physicians providing care for older patients with asthma should consider testing for allergic sensitization and counseling about environmental control practices, particularly among those with poorly controlled asthma," suggest Paula Busse (Mount Sinai … |
View full post on asthma – Google News
| Related Articles |
SHP-1 Regulation of Mast Cell Function in Allergic Inflammation and Anaphylaxis.
PLoS One. 2013;8(2):e55763
Authors: Zhou L, Oh SY, Zhou Y, Yuan B, Wu F, Oh MH, Wang Y, Takemoto C, Van Rooijen N, Zheng T, Zhu Z
Abstract
Allergic inflammation and severe allergic reactions (anaphylaxis) are important in allergen induced diseases. Bacterial products such as lipopolysaccharide (LPS) are ubiquitous and can facilitate allergen induced Th2 immune responses. Phosphatase SHP-1 is critical in regulating immunological homeostasis and in allergen induced Th2 immune responses in the lung. However, the mechanisms underlying the initiation of allergic inflammation and allergen induced anaphylaxis are still not completely elucidated and it is unclear whether SHP-1 plays any role in LPS-induced airway inflammation and in allergen-induced anaphylaxis. In this study we tested the hypothesis that phosphatase SHP-1 plays an important role in allergic inflammation and anaphylaxis and determined whether its effects are through regulation of mast cell functions. SHP-1 deficient (mev/+ and mev/mev) and mast cell deficient (Kit(W-sh)) mice were examined in their responses to LPS airway stimulation and to ovalbumin (OVA) allergen induced systemic anaphylaxis. Compared to wild type mice, mev/+ mice had significantly enhanced LPS induced airway inflammation and OVA induced anaphylactic responses, including hypothermia and clinical symptoms. These changes were mast cell dependent as Kit(W-sh) mice had reduced responses whereas adoptive transfer of mast cells restored the responses. However, T and B cells were not involved and macrophages did not play a significant role in LPS induced airway inflammation. Interestingly, basophil differentiation from SHP-1 deficient bone marrow cells was significantly reduced. These findings provided evidence that through regulation of mast cell functions SHP-1 plays a critical role as a negative regulator in allergic inflammation and in allergen induced anaphylaxis. In addition, SHP-1 seems to be required for normal basophil development.
PMID: 23390550 [PubMed – in process]
View full post on pubmed: asthma
 |
Multiple In Vitro and In Vivo Regulatory Effects of Budesonide in CD4+ T Lymphocyte Subpopulations of Allergic Asthmatics.
PLoS One. 2012;7(12):e48816
Authors: Pace E, Di Sano C, La Grutta S, Ferraro M, Albeggiani G, Liotta G, Di Vincenzo S, Uasuf CG, Bousquet J, Gjomarkaj M
Abstract
BACKGROUND: Increased activation and increased survival of T lymphocytes characterise bronchial asthma.
OBJECTIVES: In this study the effect of budesonide on T cell survival, on inducible co-stimulator T cells (ICOS), on Foxp3 and on IL-10 molecules in T lymphocyte sub-populations was assessed.
METHODS: Cell survival (by annexin V binding) and ICOS in total lymphocytes, in CD4+/CD25+ and in CD4+/CD25- and Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25-cells was evaluated, by cytofluorimetric analysis, in mild intermittent asthmatics (n?=?19) and in controls (n?=?15). Allergen induced T lymphocyte proliferation and the in vivo effects of budesonide in mild persistent asthmatics (n?=?6) were also explored.
RESULTS: Foxp3 was reduced in CD4+/CD25- and in CD4+/CD25+ cells and ICOS was reduced in CD4+/CD25+ cells but it was increased in CD4+CD25-in asthmatics when compared to controls. In asthmatics, in vitro, budesonide was able to: 1) increase annexin V binding and to reduce ICOS in total lymphocytes; 2) increase annexin V binding and Foxp3 and to reduce ICOS in CD4+/CD25- cells; 3) reduce annexin V binding and to increase IL-10 and ICOS in CD4+/CD25+ cells; 4) reduce cell allergen induced proliferation. In vivo, budesonide increased ICOS in CD4+/CD25+ while it increased Foxp3 and IL-10 in CD4+/CD25+ and in CD4+/CD25- cells.
CONCLUSIONS: Budesonide modulates T cell survival, ICOS, Foxp3 and IL-10 molecules differently in T lymphocyte sub-populations. The findings provided shed light on new mechanisms by which corticosteroids, drugs widely used for the clinical management of bronchial asthma, control T lymphocyte activation.
PMID: 23251336 [PubMed – in process]
View full post on pubmed: asthma
|
Hyderabad to host meet on allergic diseases
Hindu Business Line According to the World Health Organization, an estimated 300 million individuals have asthma worldwide, a figure that could increase to 400 million by 2025 if trends continue. Supported by the Union Ministry of Health and Family Welfare, the scientific … World allergy specialists to meet in Hyderabad on December 6 |
View full post on asthma – Google News